Previous 10 | Next 10 |
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments further enhance the Company ...
MENLO PARK, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its opera...
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018 Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased to 29%, from 26% in December 2018 Statistical analyses comparing IMbark clinical trial data to closely matched ...
Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue grow...
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the...
The global pharmaceutical market has been growing at a rapid rate in recent years and is expected to reach $1.57 trillion USD by 2023, signaling a major opportunity for investors to cash in on pharmaceutical stocks. Some of the factors behind the market’s growth include the ...
Geron Corporation. (GERN) Q1 2019 Results Earnings Conference Call May 16, 2019, 09:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra...
Geron ( GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more ...
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th Eur...
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with ...
News, Short Squeeze, Breakout and More Instantly...
U.S. stocks were higher, with the Dow Jones jumping over 150 points on Friday. Shares of Skechers U.S.A., Inc. (NYSE:SKX) rose sharply during Frida...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Companyȁ...
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Friday. Shares of Argan, Inc. (NYSE: AGX) rose sharply during Friday&r...